

B F Chong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9577557/publications.pdf>

Version: 2024-02-01

79
papers

1,303
citations

430874

18
h-index

414414

32
g-index

79
all docs

79
docs citations

79
times ranked

1814
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors for ANA positivity in healthy persons. <i>Arthritis Research and Therapy</i> , 2011, 13, R38.	3.5	136
2	Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis. <i>Nature Medicine</i> , 2018, 24, 617-627.	30.7	117
3	Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. <i>British Journal of Dermatology</i> , 2012, 166, 29-35.	1.5	93
4	Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 1147-1153.	3.4	61
5	Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. <i>Clinical Immunology</i> , 2016, 169, 58-68.	3.2	61
6	A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2013, 168, 145-153.	1.5	50
7	Photosensitivity in cutaneous lupus erythematosus. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2013, 29, 4-11.	1.5	50
8	Creation of an Internal Teledermatology Store-and-Forward System in an Existing Electronic Health Record. <i>JAMA Dermatology</i> , 2017, 153, 644.	4.1	47
9	Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. <i>Journal of Dermatological Science</i> , 2014, 73, 216-224.	1.9	40
10	A subset of CD163+ macrophages displays mixed polarizations in discoid lupus skin. <i>Arthritis Research and Therapy</i> , 2015, 17, 324.	3.5	40
11	Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell-Suppressor Mechanisms. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1801-1810.	0.7	38
12	IgG and IgM Autoantibody Differences in Discoid and Systemic Lupus Patients. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2770-2779.	0.7	32
13	IgG, IgM, and IgA Antinuclear Antibodies in Discoid and Systemic Lupus Erythematosus Patients. <i>Scientific World Journal</i> , The, 2014, 2014, 1-7.	2.1	26
14	Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine. <i>Dermatologic Therapy</i> , 2021, 34, e15114.	1.7	26
15	Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 694.	1.6	25
16	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. <i>British Journal of Dermatology</i> , 2020, 182, 410-417.	1.5	25
17	Changes in T cell and B cell composition in discoid lupus erythematosus skin at different stages. <i>Journal of Dermatological Science</i> , 2017, 85, 247-249.	1.9	22
18	Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study. <i>International Journal of Women's Dermatology</i> , 2018, 4, 152-158.	2.0	21

#	ARTICLE	IF	CITATIONS
19	25-Hydroxyvitamin D levels in African-American and Caucasian/Hispanic subjects with cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2012, 166, 372-379.	1.5	20
20	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus "An Ongoing Need for International Consensus and Collaborations. <i>Journal of Investigative Dermatology</i> , 2019, 139, 270-276.	0.7	18
21	Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , 2020, 156, 901.	4.1	18
22	Photoprotective habits of patients with cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 944-951.e1.	1.2	17
23	Site-Specific Analysis of Inflammatory Markers in Discoid Lupus Erythematosus Skin. <i>Scientific World Journal</i> , The, 2014, 2014, 1-12.	2.1	17
24	Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2019, 180, 1430-1437.	1.5	17
25	Detection of Type VII Collagen Autoantibodies Before the Onset of Bullous Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2015, 151, 539.	4.1	16
26	Sunscreen use in patients with cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2015, 173, 831-834.	1.5	15
27	Expansion of Myeloid-Derived Suppressor Cells in the Peripheral Blood and Lesional Skin of Cutaneous Lupus Patients. <i>Journal of Investigative Dermatology</i> , 2019, 139, 478-481.	0.7	15
28	The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 431-431.	1.7	15
29	Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19. <i>Dermatologic Therapy</i> , 2020, 33, e13834.	1.7	14
30	Understanding How Cutaneous Lupus Erythematosus Progresses to Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2014, 150, 296.	4.1	13
31	Discoid lupus erythematosus skin lesion distribution and characteristics in Black patients: a retrospective cohort study. <i>Lupus Science and Medicine</i> , 2021, 8, e000514.	2.7	13
32	Natural history of disease activity and damage in patients with cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1053-1060.e3.	1.2	12
33	Not Just Skin Deep: Systemic Disease Involvement in Patients With Cutaneous Lupus. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2017, 18, S69-S74.	0.8	11
34	Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus. <i>Annals of Translational Medicine</i> , 2021, 9, 429-429.	1.7	11
35	A Systematic Review of the Progression of Cutaneous Lupus to Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2022, 13, 866319.	4.8	11
36	Autoantibodies and Disease Activity in Patients With Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , 2014, 150, 651.	4.1	10

#	ARTICLE	IF	CITATIONS
37	Predictors of low quality of life in patients with discoid lupus. <i>British Journal of Dermatology</i> , 2017, 177, e147-e149.	1.5	9
38	Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus. <i>JAMA Dermatology</i> , 2018, 154, 712.	4.1	9
39	Modular gene analysis reveals distinct molecular signatures for subsets of patients with cutaneous lupus erythematosus*. <i>British Journal of Dermatology</i> , 2021, 185, 563-572.	1.5	9
40	Autoantibody and Clinical Profiles in Patients With Discoid Lupus and Borderline Systemic Lupus. <i>Archives of Dermatology</i> , 2012, 148, 651-5.	1.4	8
41	Practice-based differences in paediatric discoid lupus erythematosus. <i>British Journal of Dermatology</i> , 2019, 181, 805-810.	1.5	8
42	Factors associated with quality of life in cutaneous lupus erythematosus using the Revised Wilson and Cleary Model. <i>Lupus</i> , 2020, 29, 1691-1703.	1.6	7
43	Exclusion of Cutaneous Lupus Erythematosus Subtypes From the 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus: Comment on the Article by Aringer et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 1403-1404.	5.6	7
44	Development of systemic lupus in patients with cutaneous lupus using the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 200-202.	1.2	7
45	Reducing outpatient dermatology clinic wait times in a safety net health system in Dallas, Texas. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 631-632.	1.2	6
46	Differences in quality of life in patients with cutaneous lupus erythematosus with varying income levels. <i>Lupus</i> , 2021, 30, 972-980.	1.6	6
47	A cross-sectional study of no-show rates and factors contributing to nonattendance at 3 academic pediatric dermatology centers in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1169-1172.	1.2	6
48	Treatments for disease damage in cutaneous lupus erythematosus: A narrative review. <i>Dermatologic Therapy</i> , 2021, 34, e15034.	1.7	5
49	Worsening skin damage in patients with cutaneous lupus erythematosus may predict development of systemic lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 538-540.	1.2	4
50	Cost minimization analysis of mainstay treatments in cutaneous lupus erythematosus. <i>Dermatologic Therapy</i> , 2022, 35, e15190.	1.7	4
51	Decreased progression to systemic lupus erythematosus in patients with cutaneous lupus erythematosus under European League Against Rheumatism/American College of Rheumatology criteria. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 187-190.	1.2	4
52	Assessment of dermatology clinic resources at safety-net hospitals: Results from a national survey. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 977-978.e2.	1.2	3
53	T-cell polarization differs in various stages of discoid lupus erythematosus skin. <i>British Journal of Dermatology</i> , 2020, 182, 1291-1293.	1.5	3
54	Autoimmune disease development before and after cutaneous lupus erythematosus diagnosis. <i>British Journal of Dermatology</i> , 2020, 182, 1309-1310.	1.5	3

#	ARTICLE	IF	CITATIONS
55	Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy. <i>Journal of Investigative Dermatology</i> , 2022, 142, 936-943.	0.7	3
56	Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 559-566.	1.2	3
57	Ulcerative livedoid vasculopathy responding to clopidogrel. <i>JAAD Case Reports</i> , 2018, 4, 203-205.	0.8	2
58	Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial. <i>Arthritis Care and Research</i> , 2019, 71, 1425-1429.	3.4	2
59	Principal components analysis as a tool to identify lesional skin patterns in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 922-924.	1.2	2
60	Evaluation of the effect of store-and-forward teledermatology on in-person health care system utilization in a safety-net public health and hospital system. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1026-1028.	1.2	2
61	Discoid lesions and smoking history are negative predictors of disease activity remission in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1135-1137.	1.2	2
62	The Genetic Landscape of Cutaneous Lupus Erythematosus. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
63	Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020, 7, e000364.	2.7	1
64	Elevated serum levels of C-X-C motif chemokine ligand 10 can distinguish systemic lupus erythematosus patients from cutaneous lupus erythematosus patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1051-1054.	1.2	1
65	Outcomes associated with shorter wait times at a county hospital outpatient dermatology clinic. <i>Cutis</i> , 2018, 102, 159-160.	0.3	1
66	Influence of Socio-Demographic Factors in Patients With Cutaneous Lupus Erythematosus. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	1
67	Patient-reported outcomes in patients with cutaneous lupus. <i>British Journal of Dermatology</i> , 2017, 176, 7-7.	1.5	0
68	Pathogenesis of morphea: knowledge gaps in subtypes and comparisons to systemic sclerosis. <i>British Journal of Dermatology</i> , 2017, 177, 9-10.	1.5	0
69	SnapshotDx Quiz: February 2018. <i>Journal of Investigative Dermatology</i> , 2018, 138, e19.	0.7	0
70	2456 Cutaneous lupus erythematosus patients have increased circulating myeloid-derived suppressor cells with immunosuppressive properties. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 7-8.	0.6	0
71	SnapshotDx Quiz: June 2018. <i>Journal of Investigative Dermatology</i> , 2018, 138, e43.	0.7	0
72	Applying the Cutaneous Lupus Erythematosus Disease Area and Severity Index to paediatric cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2019, 180, 20-21.	1.5	0

#	ARTICLE	IF	CITATIONS
73	SnapshotDx Quiz: October 2020. Journal of Investigative Dermatology, 2020, 140, e109-e113.	0.7	0
74	SnapshotDx Quiz: June 2020. Journal of Investigative Dermatology, 2020, 140, e61-e64.	0.7	0
75	SnapshotDx Quiz: February 2021. Journal of Investigative Dermatology, 2021, 141, e15-e19.	0.7	0
76	Guidance for providers on the treatment and management of cutaneous lupus erythematosus. British Journal of Dermatology, 2021, , .	1.5	0
77	Non-adherence of surgical treatment in patients with non-melanoma skin cancer: a retrospective cohort pilot study. Archives of Dermatological Research, 2021, , 1.	1.9	0
78	SnapshotDx Quiz: February 2022. Journal of Investigative Dermatology, 2022, 142, e15-e20.	0.7	0
79	Classification of Disease Damage and Activity in Cutaneous Lupus Erythematosus: A Cross-Sectional Analysis. Journal of the American Academy of Dermatology, 2022, , .	1.2	0